Comparison of treatment models for single primary advanced gallbladder cancer DOI Creative Commons

Rongxuan Li,

Xiaohong Chen, Bingchen Wang

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Nov. 13, 2024

Purpose Treatment for advanced gallbladder cancer (GBC) remains controversial, with various recommendations regarding the choice and combination of surgery adjuvant therapy. The present article is targeting exploration optimal treatment models GBC. Methods AJCC (American Joint Committee on Cancer, 8th edition) stage III IV GBC, were defined as Patients GBC identified using Surveillance, Epidemiology, End Results (SEER) database departmental cohort. Because most representative, only adenocarcinoma (GBAC) patients selected. Based their surgical status (No, Non-radical Radical surgery), chemotherapy (Chemotherapy, No chemotherapy), radiotherapy (Radiotherapy, radiotherapy), categorized. For purposes evaluating outcomes determining risk element cancer-specific survival (CSS), Cox regression analysis was applied. Kaplan-Meier curves used before after adjusting covariates, log-rank tests to analyze discrepancies between curves. Immunotherapy analyzed clinical data from Finally, compensate limitations database, a review examines progress in 5,154 aged over 18 years solitary primary SEER database. In patients, model has emerged significant prognostic factor. “Radical + Chemotherapy Radiotherapy” maximally improved CSS while “No radiotherapy” had lowest CSS. conclusions supported even subgroup by stage. efficacy immunotherapy demonstrated cohort analysis. Additionally, this provides comprehensive overview recent advancements emerging strategies. Conclusion Even when cannot be pursued, providing combinations treatments whenever possible always beneficial survival.

Language: Английский

Efficacy and biomarker analysis of second‐line nab‐paclitaxel plus sintilimab in patients with advanced biliary tract cancer DOI Creative Commons

Xiaofen Li,

Nan Zhou, Yang Yu

et al.

Cancer Science, Journal Year: 2024, Volume and Issue: 115(7), P. 2371 - 2383

Published: April 18, 2024

Abstract Biliary tract cancer (BTC) is a highly aggressive malignancy with limited second‐line therapy. We conducted this phase 2 trial to evaluate the efficacy and safety of nab‐paclitaxel plus sintilimab in advanced BTC. Histologically confirmed BTC patients documented disease progression after first‐line chemotherapy were enrolled. Subjects received 125 mg/m on days 1 8 200 mg day 1, administered every 3 weeks. The primary end point was objective response rate (ORR). secondary points progression‐free survival (PFS), overall (OS), adverse reactions. Simultaneously, next‐generation sequencing, programmed cell death ligand immunohistochemistry multiplex immunofluorescence tumor‐infiltrating lymphocytes applied explore potential biomarkers. Twenty‐six subjects consecutively ORR 26.9% (7/26), including two complete responses five partial responses, which met point. control 61.5% (16/26). median PFS 169 (about 5.6 months, 95% confidence interval [CI] 60–278 days). OS 442 14.7 CI 298–586 Grade treatment‐related events (TRAEs) mainly anemia (27%), leukopenia (23%), neutropenia (19%), peripheral sensory neuropathy (8%). No grade 4 or 5 TRAEs occurred. Biomarker analysis suggested that positive PD‐L1 high proportions CD8 + T‐cell infiltration correlated improved clinical outcome. Nab‐paclitaxel potentially effective tolerable regimen for deserves be studied large‐scale trials. status T might promising biomarkers prediction.

Language: Английский

Citations

2
Comparison of treatment models for single primary advanced gallbladder cancer DOI Creative Commons

Rongxuan Li,

Xiaohong Chen, Bingchen Wang

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Nov. 13, 2024

Purpose Treatment for advanced gallbladder cancer (GBC) remains controversial, with various recommendations regarding the choice and combination of surgery adjuvant therapy. The present article is targeting exploration optimal treatment models GBC. Methods AJCC (American Joint Committee on Cancer, 8th edition) stage III IV GBC, were defined as Patients GBC identified using Surveillance, Epidemiology, End Results (SEER) database departmental cohort. Because most representative, only adenocarcinoma (GBAC) patients selected. Based their surgical status (No, Non-radical Radical surgery), chemotherapy (Chemotherapy, No chemotherapy), radiotherapy (Radiotherapy, radiotherapy), categorized. For purposes evaluating outcomes determining risk element cancer-specific survival (CSS), Cox regression analysis was applied. Kaplan-Meier curves used before after adjusting covariates, log-rank tests to analyze discrepancies between curves. Immunotherapy analyzed clinical data from Finally, compensate limitations database, a review examines progress in 5,154 aged over 18 years solitary primary SEER database. In patients, model has emerged significant prognostic factor. “Radical + Chemotherapy Radiotherapy” maximally improved CSS while “No radiotherapy” had lowest CSS. conclusions supported even subgroup by stage. efficacy immunotherapy demonstrated cohort analysis. Additionally, this provides comprehensive overview recent advancements emerging strategies. Conclusion Even when cannot be pursued, providing combinations treatments whenever possible always beneficial survival.

Language: Английский

Citations

1